BioPharma Dive December 23, 2025
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
In a year marked by volatility, a transatlantic optimism gap has emerged between the pharma C-suite in the U.S. and their overseas counterparts, with Americans taking the glass-half-empty view, according to a recent Deloitte survey.
“The differences between how European and Asian biopharma leaders felt about where the industry was headed was a really stark difference to the United States,” said Pete Lyons, vice chair and leader of the U.S. Life Sciences practice at Deloitte.
About 90% of European and Asian leaders were positive or cautiously positive compared to less than 60% in the U.S., which was a “fairly...
Today's Sponsors
Today's Sponsor